haku: @freeterm ownership / yhteensä: 84
viite: 39 / 84
| Tekijä: | Lippman, S. Rosan, D.E. Seitchik, A. |
| Otsikko: | Why lower drug prices benefit institutional investors: An application of universal ownership theory |
| Lehti: | Corporate governance
2007 : MAY, VOL. 15:3, p. 455-466 |
| Asiasana: | institutional investors pharmaceutical industry prices health service costs social responsibility theories |
| Vapaa asiasana: | ownership |
| Kieli: | eng |
| Tiivistelmä: | This paper deals with the net impact of cuts in drug prices (here as: d-prs.) on investor portfolios. It is found that falls in pharmaceutical company profits resulting from price cuts would be largely, if not fully, offset by a combination of health plan cost savings and increases in consumer spending power. In addition, falling d-prs. benefit investors through the dynamic benefits from a healthier workforce with greater access to prescription drugs. It is concluded that (as to the "universal investor"s perspective), support for lower d-prs. is consistent with a fiduciary duty to seek attractive long-term returns at the portfolio level. |
SCIMA